VDRM ViaDerma Inc

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced that it remains fully operational and is actively working to complete its overdue annual and quarterly financial reports.

The company is not defunct and continues to pursue its business objectives. ViaDerma is currently exploring all strategic options to move the company forward in the most effective manner possible.

About ViaDerma, Inc.

ViaDerma, Inc. (OTC Expert Market: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal drug delivery technology solutions to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: .

Any forecast of future performance is a "forward-looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

Contact information:

Investor Relations

Email:

Phone: 310-734-6111



EN
04/06/2025

Underlying

VDRMViaDerma Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ViaDerma Inc

 PRESS RELEASE
Free
VDRM VIADERMA INC

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulator...

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced that it remains fully operational and is actively working to complete its overdue annual and quarterly financial reports. The company is not defunct and continues to pursue its business objectives. ViaDerma is currently exploring all strategic options to move the company forward in the most effective manner possible. About ViaDerma, Inc.ViaDerma, Inc. (OTC Expert Mar...

June 4, 2025 1 EN
 PRESS RELEASE
Free
VDRM VIADERMA INC

ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and ...

ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India LOS ANGELES, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, is pleased to announce the opening of a satellite office in Dubai to facilitate its ongoing expansion in the Middle East. Local regulations require businesses to maintain a physical office within the region to conduct commercial operations, making this a strategic move to further ViaDerma's growth and accessibility in the...

January 21, 2025 1 EN
 PRESS RELEASE
Free
VDRM VIADERMA INC

ViaDerma Announces Significant 2024 Achievements and International Exp...

ViaDerma Announces Significant 2024 Achievements and International Expansion LOS ANGELES, Dec. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, proudly announces the completion of a landmark year marked by significant global expansion and operational milestones. As the company continues its mission to deliver cutting-edge pharmaceutical products to underserved markets, 2024 has proven to be a transformative year. ViaDerma’s expansion efforts in 2024 have led to a remarkable increase in personnel, with...

December 10, 2024 1 EN
 PRESS RELEASE
Free
VDRM VIADERMA INC

ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving...

ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth LOS ANGELES, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, announced its financial results for the second quarter and six-month period ending June 30, 2024. The company delivered a strong financial performance with notable revenue consistency, positive net income, and a robust increase in cash reserves. Financial Highlights for Q2 2024: Revenue: ViaDerma maintained stead...

October 3, 2024 1 EN
 PRESS RELEASE
Free
VDRM VIADERMA INC

ViaDerma Completes First Shipment of 500,000 Units to Nigeria

ViaDerma Completes First Shipment of 500,000 Units to Nigeria A second shipment of 500,000 units is expected to be made by the end of October LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a specialty pharmaceutical company known for developing innovative transdermal drug delivery systems, is pleased to announce the successful completion of its first shipment of 500,000 units of its flagship product, a tetracycline based topical antibiotic to Nigeria. The shipment was sent out as planned before the end of August 2024. This milestone marks a significant st...

September 10, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch